The quarterly report is out. It says the usual pile of nothingness wrapped in the the standard gobbledygook of warrants and convertible this or that. They still claim to be planning to start two clinical trials, but they have been saying this for a number of years now, so it doesn't mean anything. The only "news" of note is the sales of AlloRx for offshore treatments is picking up significantly, as demand for stem cell therapy picks up. If you missed it, an NFL quarterback (Kirk Cousins) was treated recently with AlloRx. So, who knows , maybe that business will grow and keep them afloat. "For whom and for what" is separate question, as the company seems on a 100-year path to nowhere, as though stockholders have the lifespans of biblical patriarchs.